

David K Chang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4703848/publications.pdf>

Version: 2024-02-01

82
papers

15,193
citations

66343

42
h-index

60623

81
g-index

86
all docs

86
docs citations

86
times ranked

20786
citing authors

#	ARTICLE	IF	CITATIONS
1	ICGC-ARGO precision medicine: familial matters in pancreatic cancer. <i>Lancet Oncology</i> , The, 2022, 23, 25-26.	10.7	6
2	Spatial expression of IKK-alpha is associated with a differential mutational landscape and survival in primary colorectal cancer. <i>British Journal of Cancer</i> , 2022, , .	6.4	2
3	ICGC-ARGO precision medicine: targeted therapy according to longitudinal assessment of tumour heterogeneity in colorectal cancer. <i>Lancet Oncology</i> , The, 2022, 23, 463-464.	10.7	3
4	Targeting DNA Damage Response and Replication Stress in Pancreatic Cancer. <i>Gastroenterology</i> , 2021, 160, 362-377.e13.	1.3	90
5	Molecular Subtyping of Pancreatic Cancer. , 2021, , 305-319.		0
6	DNA methylation patterns identify subgroups of pancreatic neuroendocrine tumors with clinical association. <i>Communications Biology</i> , 2021, 4, 155.	4.4	26
7	Muscle-Derived Cytokines Reduce Growth, Viability and Migratory Activity of Pancreatic Cancer Cells. <i>Cancers</i> , 2021, 13, 3820.	3.7	12
8	Homologous Recombination Deficiency in Pancreatic Cancer: A Systematic Review and Prevalence Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2021, 39, 2617-2631.	1.6	63
9	Role of PLEXIND1/TGFÎ² Signaling Axis in Pancreatic Ductal Adenocarcinoma Progression Correlates with the Mutational Status of KRAS. <i>Cancers</i> , 2021, 13, 4048.	3.7	4
10	Molecular Subtyping and Precision Medicine for Pancreatic Cancer. <i>Journal of Clinical Medicine</i> , 2021, 10, 149.	2.4	34
11	Modulation of pancreatic cancer cell sensitivity to FOLFIRINOX through microRNA-mediated regulation of DNA damage. <i>Nature Communications</i> , 2021, 12, 6738.	12.8	10
12	Precision Oncology in Surgery. <i>Annals of Surgery</i> , 2020, 272, 366-376.	4.2	48
13	Clinical and Molecular Risk Factors for Recurrence Following Radical Surgery of Well-Differentiated Pancreatic Neuroendocrine Tumors. <i>Frontiers in Medicine</i> , 2020, 7, 385.	2.6	7
14	Defining the clinical genomic landscape for real-world precision oncology. <i>Genomics</i> , 2020, 112, 5324-5330.	2.9	16
15	HNF4A and GATA6 Loss Reveals Therapeutically Actionable Subtypes in Pancreatic Cancer. <i>Cell Reports</i> , 2020, 31, 107625.	6.4	78
16	Altered RNA Splicing by Mutant p53 Activates Oncogenic RAS Signaling in Pancreatic Cancer. <i>Cancer Cell</i> , 2020, 38, 198-211.e8.	16.8	99
17	An unbiased high-throughput drug screen reveals a potential therapeutic vulnerability in the most lethal molecular subtype of pancreatic cancer. <i>Molecular Oncology</i> , 2020, 14, 1800-1816.	4.6	10
18	Reasons to be testing: the dawn of complex molecular profiling in routine oncology practice. <i>Annals of Oncology</i> , 2019, 30, 1691-1694.	1.2	12

#	ARTICLE	IF	CITATIONS
19	Molecular subtypes of pancreatic cancer. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019, 16, 207-220.	17.8	573
20	Feasibility and clinical utility of endoscopic ultrasound guided biopsy of pancreatic cancer for next-generation molecular profiling. <i>Chinese Clinical Oncology</i> , 2019, 8, 16-16.	1.2	33
21	Tailored first-line and second-line CDK4-targeting treatment combinations in mouse models of pancreatic cancer. <i>Gut</i> , 2018, 67, 2142-2155.	12.1	100
22	Interrogating open issues in cancer precision medicine with patient-derived xenografts. <i>Nature Reviews Cancer</i> , 2017, 17, 254-268.	28.4	527
23	Whole-genome landscape of pancreatic neuroendocrine tumours. <i>Nature</i> , 2017, 543, 65-71.	27.8	716
24	Recurrent noncoding regulatory mutations in pancreatic ductal adenocarcinoma. <i>Nature Genetics</i> , 2017, 49, 825-833.	21.4	55
25	Pancreatic Cancer Genomes: Implications for Clinical Management and Therapeutic Development. <i>Clinical Cancer Research</i> , 2017, 23, 1638-1646.	7.0	136
26	BRCA2 secondary mutation-mediated resistance to platinum and PARP inhibitor-based therapy in pancreatic cancer. <i>British Journal of Cancer</i> , 2017, 116, 1021-1026.	6.4	61
27	Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma. <i>Cancer Cell</i> , 2017, 32, 185-203.e13.	16.8	1,428
28	Lost in translation: returning germline genetic results in genome-scale cancer research. <i>Genome Medicine</i> , 2017, 9, 41.	8.2	27
29	Hypermethylation In Pancreatic Cancer. <i>Gastroenterology</i> , 2017, 152, 68-74.e2.	1.3	174
30	The role of induction chemotherapy + chemoradiotherapy in localised pancreatic cancer: initial experience in Scotland. <i>Journal of Gastrointestinal Oncology</i> , 2017, 8, 683-695.	1.4	12
31	PDX1 dynamically regulates pancreatic ductal adenocarcinoma initiation and maintenance. <i>Genes and Development</i> , 2016, 30, 2669-2683.	5.9	88
32	Exploiting the neoantigen landscape for immunotherapy of pancreatic ductal adenocarcinoma. <i>Scientific Reports</i> , 2016, 6, 35848.	3.3	127
33	Gastric cancer: Australian outcomes of multi-modality treatment with curative intent. <i>ANZ Journal of Surgery</i> , 2016, 86, 386-390.	0.7	3
34	Resolution of Novel Pancreatic Ductal Adenocarcinoma Subtypes by Global Phosphotyrosine Profiling. <i>Molecular and Cellular Proteomics</i> , 2016, 15, 2671-2685.	3.8	29
35	CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma. <i>Cancer Cell</i> , 2016, 29, 832-845.	16.8	645
36	Ampullary Cancers Harbor ELF3 Tumor Suppressor Gene Mutations and Exhibit Frequent WNT Dysregulation. <i>Cell Reports</i> , 2016, 14, 907-919.	6.4	107

#	ARTICLE	IF	CITATIONS
37	Genomic analyses identify molecular subtypes of pancreatic cancer. <i>Nature</i> , 2016, 531, 47-52.	27.8	2,700
38	Targeting the <sc>LOX</sc> / <sc>hypoxia</sc> axis reverses many of the features that make pancreatic cancer deadly: inhibition of <sc>LOX</sc> abrogates metastasis and enhances drug efficacy. <i>EMBO Molecular Medicine</i> , 2015, 7, 1063-1076.	6.9	223
39	The epigenetic agents suberoylanilide hydroxamic acid and 5-AZA-2â€² deoxycytidine decrease cell proliferation, induce cell death and delay the growth of MiaPaCa2 pancreatic cancer cells in vivo. <i>International Journal of Oncology</i> , 2015, 46, 2223-2230.	3.3	17
40	Pancreatic cancer genomics: where can the science take us?. <i>Clinical Genetics</i> , 2015, 88, 213-219.	2.0	13
41	Inherited Susceptibility to Pancreatic Cancer in the Era of Next-Generation Sequencing. <i>Gastroenterology</i> , 2015, 148, 496-498.	1.3	3
42	Whole genomes redefine the mutational landscape of pancreatic cancer. <i>Nature</i> , 2015, 518, 495-501.	27.8	2,132
43	Precision Medicine for Advanced Pancreas Cancer: The Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) Trial. <i>Clinical Cancer Research</i> , 2015, 21, 2029-2037.	7.0	209
44	Cancer Genetics and Implications for Clinical Management. <i>Surgical Clinics of North America</i> , 2015, 95, 919-934.	1.5	6
45	Asian gastric cancer patients show superior survival: the experiences of a single Australian center. <i>Gastric Cancer</i> , 2015, 18, 256-261.	5.3	15
46	Connective tissue growth factor as a novel therapeutic target in high grade serous ovarian cancer. <i>Oncotarget</i> , 2015, 6, 44551-44562.	1.8	37
47	Adjuvant chemotherapy in elderly patients with pancreatic cancer. <i>British Journal of Cancer</i> , 2014, 110, 313-319.	6.4	64
48	Stratified Medicine for Pancreatic Cancer. , 2014, , 807-814.		0
49	Clinical and pathologic features of familial pancreatic cancer. <i>Cancer</i> , 2014, 120, 3669-3675.	4.1	53
50	Can we move towards personalised pancreatic cancer therapy?. <i>Expert Review of Gastroenterology and Hepatology</i> , 2014, 8, 335-338.	3.0	5
51	Genome-wide DNA methylation patterns in pancreatic ductal adenocarcinoma reveal epigenetic deregulation of SLITâ€’ROBO, ITGA2 and MET signaling. <i>International Journal of Cancer</i> , 2014, 135, 1110-1118.	5.1	192
52	Targeting mTOR dependency in pancreatic cancer. <i>Gut</i> , 2014, 63, 1481-1489.	12.1	107
53	Mining the genomes of exceptional responders. <i>Nature Reviews Cancer</i> , 2014, 14, 291-292.	28.4	38
54	Returning individual research results for genome sequences of pancreatic cancer. <i>Genome Medicine</i> , 2014, 6, 42.	8.2	25

#	ARTICLE	IF	CITATIONS
55	Pancreatic cancer genomics. <i>Current Opinion in Genetics and Development</i> , 2014, 24, 74-81.	3.3	50
56	Personalising pancreas cancer treatment: When tissue is the issue. <i>World Journal of Gastroenterology</i> , 2014, 20, 7849.	3.3	22
57	Understanding pancreatic cancer genomes. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2013, 20, 549-556.	2.6	31
58	Clinical and molecular characterization of HER2 amplified-pancreatic cancer. <i>Genome Medicine</i> , 2013, 5, 78.	8.2	97
59	Histomolecular Phenotypes and Outcome in Adenocarcinoma of the Ampulla of Vater. <i>Journal of Clinical Oncology</i> , 2013, 31, 1348-1356.	1.6	142
60	The histone deacetylase SIRT2 stabilizes Myc oncoproteins. <i>Cell Death and Differentiation</i> , 2013, 20, 503-514.	11.2	171
61	Neuropilin-2 Promotes Extravasation and Metastasis by Interacting with Endothelial $\alpha 5$ Integrin. <i>Cancer Research</i> , 2013, 73, 4579-4590.	0.9	97
62	Reply to G.F. Arroyo. <i>Journal of Clinical Oncology</i> , 2013, 31, 3843-3844.	1.6	0
63	Somatic Point Mutation Calling in Low Cellularity Tumors. <i>PLoS ONE</i> , 2013, 8, e74380.	2.5	67
64	The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma. <i>Nature</i> , 2012, 486, 266-270.	27.8	297
65	The prognostic and predictive value of serum CA19.9 in pancreatic cancer. <i>Annals of Oncology</i> , 2012, 23, 1713-1722.	1.2	240
66	<i>Sleeping Beauty</i> mutagenesis reveals cooperating mutations and pathways in pancreatic adenocarcinoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 5934-5941.	7.1	201
67	RON is not a prognostic marker for resectable pancreatic cancer. <i>BMC Cancer</i> , 2012, 12, 395.	2.6	17
68	Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. <i>Nature</i> , 2012, 491, 399-405.	27.8	1,741
69	Recruitment and Activation of Pancreatic Stellate Cells from the Bone Marrow in Pancreatic Cancer: A Model of Tumor-Host Interaction. <i>PLoS ONE</i> , 2011, 6, e26088.	2.5	55
70	Retinoid Signaling in Pancreatic Cancer, Injury and Regeneration. <i>PLoS ONE</i> , 2011, 6, e29075.	2.5	20
71	Clinical and immunohistochemical features of 34 solid pseudopapillary tumors of the pancreas. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011, 26, 267-274.	2.8	53
72	Preclinical strategies to define predictive biomarkers for therapeutically relevant cancer subtypes. <i>Human Genetics</i> , 2011, 130, 93-101.	3.8	13

#	ARTICLE	IF	CITATIONS
73	Transcriptional upregulation of histone deacetylase 2 promotes Myc-induced oncogenic effects. <i>Oncogene</i> , 2010, 29, 5957-5968.	5.9	76
74	Synoptic reporting improves histopathological assessment of pancreatic resection specimens. <i>Pathology</i> , 2009, 41, 161-167.	0.6	94
75	Margin Clearance and Outcome in Resected Pancreatic Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 2855-2862.	1.6	296
76	Taking optical biopsies with confocal endomicroscopy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2009, 24, 1701-1703.	2.8	6
77	Role of endoscopic ultrasound in pancreatic cancer. <i>Expert Review of Gastroenterology and Hepatology</i> , 2009, 3, 293-303.	3.0	12
78	Expression of S100A2 Calcium-Binding Protein Predicts Response to Pancreatectomy for Pancreatic Cancer. <i>Gastroenterology</i> , 2009, 137, 558-568.e11.	1.3	82
79	Real Time Intraoperative Confocal Laser Microscopy-Guided Surgery. <i>Annals of Surgery</i> , 2009, 249, 735-737.	4.2	22
80	Improving outcomes for operable pancreatic cancer: Is access to safer surgery the problem?. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2008, 23, 1036-1045.	2.8	29
81	Individualizing therapy for pancreatic cancer. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2008, 23, 1779-1782.	2.8	6
82	Aniseikonia, metamorphopsia and perceived entoptic pattern: some effects of a macular epiretinal membrane, and the subsequent spontaneous separation of the membrane. <i>Ophthalmic and Physiological Optics</i> , 1995, 15, 339-343.	2.0	23